Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory

被引:0
|
作者
Li, Luwei [1 ,2 ]
Zhong, Hongmei [1 ,2 ]
Wang, Yajie [1 ,2 ]
Pan, Zongying [1 ,2 ]
Xu, Shumei [1 ,2 ]
Li, Shuai [1 ,2 ]
Zeng, Guilin [2 ]
Zhang, Weiwei [2 ]
Li, Jie [3 ]
He, Lang [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Canc Prevent & Treatment Inst Chengdu, Dept Oncol,Clin Med Coll 2,Affiliated Peoples Hosp, Chengdu, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Ctr Med Res & Translat, Chengdu, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2024年 / 14卷
关键词
biomarkers of intestinal flora; immunotherapy; non-small cell lung cancer; TCM syndrome type; immune microenvironment; lung and large intestine; INVASIVE PULMONARY ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; GUT MICROBIOME; GRADING SYSTEM; DYSBIOSIS; EPIDEMIOLOGY; EFFICACY;
D O I
10.3389/fcimb.2024.1341032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective This study is aim to discern the Traditional Chinese Medicine (TCM) syndrome classifications relevant to immunotherapy sensitive in non-small cell lung cancer (NSCLC) patients, and to delineate intestinal microbiota biomarkers and impact that wield influence over the efficacy of NSCLC immunotherapy, grounded in the TCM theory of "lung and large intestine stand in exterior-interior relationship."Methods The study cohort consisted of patients with advanced NSCLC who received treatment at the Oncology Department of Chengdu Fifth People's Hospital. These patients were categorized into distinct TCM syndrome types and subsequently administered immune checkpoint inhibitors (ICIs), specifically PD-1 inhibitors. Stool specimens were collected from patients both prior to and following treatment. To scrutinize the differences in microbial gene sequences and species of the intestinal microbiota, 16S rRNA amplicon sequencing technology was employed. Additionally, peripheral blood samples were collected, and the analysis encompassed the assessment of T lymphocyte subsets and myeloid suppressor cell subsets via flow cytometry. Subsequently, alterations in the immune microenvironment pre- and post-treatment were thoroughly analyzed.Results The predominant clinical manifestations of advanced NSCLC patients encompassed spleen-lung Qi deficiency syndrome and Qi-Yin deficiency syndrome. Notably, the latter exhibited enhanced responsiveness to ICIs with a discernible amelioration of the immune microenvironment. Following ICIs treatment, significant variations in microbial abundance were identified among the three strains: Clostridia, Lachnospiraceae, and Lachnospirales, with a mutual dependency relationship. In the subset of patients manifesting positive PD-L1 expression and enduring therapeutic benefits, the study recorded marked increases in the ratios of CD3+%, CD4+%, and CD4+/CD8+ within the T lymphocyte subsets. Conversely, reductions were observed in the ratios of CD8%, Treg/CD4+, M-MDSC/MDSC, and G-MDSC/MDSC.Conclusion The strains Clostridia, Lachnospiraceae, and Lachnospirales emerge as potential biomarkers denoting the composition of the intestinal microbiota in the NSCLC therapy. The immunotherapy efficacy of ICIs markedly accentuates in patients displaying durable treatment benefits and those expressing positive PD-L1.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [32] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    Experimental Hematology & Oncology, 8
  • [33] Relationship between obstructive lung disease and non-small cell lung cancer
    Akamine, Takaki
    Tagawa, Tetsuzo
    Mori, Masaki
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 1145 - 1146
  • [34] Decrease of benefit from immune checkpoint inhibitors in women with non-small cell lung cancer
    Pinto, Joseph A.
    Mas, Luis A.
    Vallejos, Carlos S.
    Araujo, Jhajaira
    Bravo, Leny
    Aguilar, Alfredo
    Morante, Zaida
    Bretel, Denisse
    Gomez, Henry L.
    Rolfo, Christian
    CANCER RESEARCH, 2017, 77
  • [35] The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.
    Makiguchi, Tomonori
    Tanaka, Hisashi
    Taima, Kageaki
    Tatsuo, Soichiro
    Iida, Saya
    Kakeda, Shingo
    Tasaka, Sadatomo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Correlation between toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients
    Ayala de Miguel, P.
    Arnaiz Diez, S.
    Gorospe Garcia, I.
    Lopez Gallego, J.
    Illan Varella, A.
    Borrega Garcia, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
    Hirsh, Vera
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [38] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [39] Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
    Ding, Haiying
    Xin, Wenxiu
    Tong, Yinghui
    Sun, Jiao
    Xu, Gaoqi
    Ye, Ziqi
    Rao, Yuefeng
    PLOS ONE, 2020, 15 (09):
  • [40] Emerging Immunotherapies in the Treatment of Non-small Cell Lung Cancer (NSCLC) The Role of Immune Checkpoint Inhibitors
    Langer, Corey J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (04): : 422 - 430